LIVIVO - Search results -

Search results

Result 1 - 10 of total 87

Search options

Book: Hyperkalemia: from pathophysiology to treatment

Adler, Sharon G.

(Nephrology, dialysis, transplantation ; volume 34, number S3 (December 2019))

2019

Author's details	guest edited by Sharon G. Adler and Giovambattista Capasso
Series title	Nephrology, dialysis, transplantation ; volume 34, number S3 (December 2019)
Collection
Language	English
Size	iii68 Seiten, Illustrationen
Publisher	Oxford University Press
Publishing place	Oxford
Publishing country	Great Britain
Document type	Book
HBZ-ID	HT020382997
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
Zs A 2198 -34,S3-	not available for loan	Zeitschriften-Lesesaal

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Diabetic kidney disease treatment: new perspectives.

Tong, Li-Li / Adler, Sharon G

Kidney research and clinical practice

2022 Volume 41, Issue Suppl 2, Page(s) S63–S73

Abstract: Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease and end-stage kidney disease worldwide, as the obesity epidemic and the burden of diabetes continue to rise globally. In general, guideline management of patients with DKD ... ...

Abstract	Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease and end-stage kidney disease worldwide, as the obesity epidemic and the burden of diabetes continue to rise globally. In general, guideline management of patients with DKD recommends lifestyle modifications, blood pressure and glycemic control, and dyslipidemia treatment along with other cardiovascular disease risk reduction measures. The inhibition of the renin-angiotensin system (RAS) using an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker remains the foundational therapy for DKD. In type 2 diabetes (T2D), significant advances in therapeutics, including the sodium-glucose cotransporter-2 inhibitors (SGLT2i), the glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the nonsteroidal mineralocorticoid receptor agonist (MRA) finerenone, have dramatically expanded the armamentarium for treating DKD and its cardiovascular complications. Initiating, optimizing, and sustaining evidence-based pharmacological therapy using a therapeutic combination of RAS inhibitor + SGLT2i/GLP-1 RA + nonsteroidal MRA + statin is likely to significantly improve outcomes for T2D with DKD. Research into potential novel therapeutic targets for DKD remains particularly active and brings much anticipation and optimism to this field.
Language	English
Publishing date	2022-09-30
Publishing country	Korea (South)
Document type	Journal Article
ZDB-ID	2656420-8
ISSN	2211-9132
ISSN	2211-9132
DOI	10.23876/j.krcp.21.288
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Gaining Ground in Glomerular Diseases.

Adler, Sharon G / Nast, Cynthia C

Glomerular diseases

2021 Volume 1, Issue 1, Page(s) 1–2

Language	English
Publishing date	2021-03-09
Publishing country	Switzerland
Document type	Editorial
ISSN	2673-3633
ISSN (online)	2673-3633
DOI	10.1159/000515389
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The International Society of Glomerular Disease: Building the Future of Glomerular Medicine.

Damashek, Laurel J / Adler, Sharon G / Tarnoff, Joshua M / Huber, Tobias B

Glomerular diseases

2023 Volume 3, Issue 1, Page(s) 230–232

Language	English
Publishing date	2023-10-10
Publishing country	Switzerland
Document type	Editorial
ISSN	2673-3633
ISSN (online)	2673-3633
DOI	10.1159/000534536
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Diabetic Kidney Disease.

Tong, Lili / Adler, Sharon G

Clinical journal of the American Society of Nephrology : CJASN

2017 Volume 13, Issue 2, Page(s) 335–338

MeSH term(s)	Angiotensin Receptor Antagonists/adverse effects ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Biomarkers/blood ; Biopsy ; Blood Glucose/drug effects ; Blood Glucose/metabolism ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/physiopathology ; Cardiovascular Diseases/prevention & control ; Clinical Decision-Making ; Decision Support Techniques ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/drug therapy ; Diabetic Nephropathies/diagnosis ; Diabetic Nephropathies/etiology ; Diabetic Nephropathies/physiopathology ; Diabetic Nephropathies/therapy ; Disease Progression ; Diuretics/adverse effects ; Diuretics/therapeutic use ; Female ; Glomerular Filtration Rate/drug effects ; Hemodynamics/drug effects ; Humans ; Hypoglycemic Agents/adverse effects ; Hypoglycemic Agents/therapeutic use ; Kidney/drug effects ; Kidney/pathology ; Kidney/physiopathology ; Kidney Failure, Chronic/etiology ; Kidney Failure, Chronic/physiopathology ; Kidney Failure, Chronic/prevention & control ; Middle Aged ; Predictive Value of Tests ; Renin-Angiotensin System/drug effects ; Treatment Outcome
Chemical Substances	Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Biomarkers ; Blood Glucose ; Diuretics ; Hypoglycemic Agents
Language	English
Publishing date	2017-10-18
Publishing country	United States
Document type	Clinical Conference ; Journal Article
ZDB-ID	2226665-3
ISSN	1555-905X ; 1555-9041
ISSN (online)	1555-905X
ISSN	1555-9041
DOI	10.2215/CJN.04650417
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6584: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Prevalence and Management of Diabetic Nephropathy in Western Countries.

Satirapoj, Bancha / Adler, Sharon G

Kidney diseases (Basel, Switzerland)

2015 Volume 1, Issue 1, Page(s) 61–70

Abstract: Background: Diabetic nephropathy (DN) often results in end-stage renal disease, and this is the most common reason for initiation of dialysis in the United States. Complications of diabetes, particularly renal disease, substantially increase the risk of ...

Abstract	Background: Diabetic nephropathy (DN) often results in end-stage renal disease, and this is the most common reason for initiation of dialysis in the United States. Complications of diabetes, particularly renal disease, substantially increase the risk of subsequent severe illness and death. The prevalence of DN is still rising dramatically, with concomitant increases in associated mortality and cardiovascular complications. Summary: Renal involvement in type 1 and type 2 diabetes reflects a complex pathogenesis. Various genetic and environmental factors determine the susceptibility and progression to advanced stages of the disease. DN should be considered in patients who have had type 1 diabetes for at least 10 years with microalbuminuria and diabetic retinopathy, as well as in patients with type 1 or type 2 diabetes with macroalbuminuria in whom other causes for proteinuria are absent. The glomerular characteristic features include mesangial expansion, thickened glomerular basement membrane, and hyalinosis of arterioles. The optimal therapy of DN continues to evolve. For all diabetic patients, practical management including blood glucose and blood pressure control with renin-angiotensin-aldosterone blockade combined with lipid control, dietary salt restriction, lowering the dietary protein intake, increased physical activity, weight reduction, and smoking cessation can reduce the rate of progression of nephropathy and cardiovascular disease. Key message: DN is a complex disease linking hemodynamic and metabolic pathways with oxidative stress, and systemic inflammation. We summarize the current evidence of epidemiology, clinical diagnosis, and the current management of DN in Western countries. Facts from east and west: The prevalence of DN is increasing in Asia and Western countries alike. The deletion (D) allele of the angiotensin-converting enzyme gene is associated with progression to end-stage renal disease in Asian patients with DN, but this association is uncertain in Europeans. An association between DN and polymorphism of the gene coding for acetyl coenzyme A carboxylase β has been reported in Asian and Western populations. Both in Japan and the US, criteria for diagnosis are a 5-year history of diabetes and persistent albuminuria. Renal biopsy should be done in patients with severe hematuria, cellular casts and - in the US - hepatitis and HIV to rule out other pathologies. Diabetic retinopathy is considered a key criterion in Japan, but the absence of it does not rule out DN in the US. Enlargement of the kidney is observed as a diagnostic criterion in Japan. The differential use of renal biopsy as diagnostic tool might account for a different prevalence between Asian countries. Some Japanese diabetic patients show typical histological alterations for DN with a normal ACR and GFR. The clinical classification is similar between Japan and the US including five stages based on ACR and GFR. The Japanese guidelines do not include blood pressure values for the classification of DN. Guidelines for DN treatment are evolving quickly both in Asia and Western countries based on the numerous clinical trials performed worldwide. Targeting the angiotensin system for its hemodynamic and nonhemodynamic effects is a common approach. DPP-4 inhibitors are widely used in Japan and might have a higher glucose-lowering effect in Asian patients due to their specific diet. A randomized, double-blind placebo-controlled study has been launched to assess the efficacy of the Chinese herbal tea extract Shenyan Kangfu in DN.
Language	English
Publishing date	2015-05-01
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2817963-8
ISSN	2296-9357 ; 2296-9381
ISSN (online)	2296-9357
ISSN	2296-9381
DOI	10.1159/000382028
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Comprehensive approach to diabetic nephropathy.

Satirapoj, Bancha / Adler, Sharon G

Kidney research and clinical practice

2014 Volume 33, Issue 3, Page(s) 121–131

Abstract: Diabetic nephropathy (DN) is a leading cause of mortality and morbidity in patients with diabetes. This complication reflects a complex pathophysiology, whereby various genetic and environmental factors determine susceptibility and progression to end- ... ...

Abstract	Diabetic nephropathy (DN) is a leading cause of mortality and morbidity in patients with diabetes. This complication reflects a complex pathophysiology, whereby various genetic and environmental factors determine susceptibility and progression to end-stage renal disease. DN should be considered in patients with type 1 diabetes for at least 10 years who have microalbuminuria and diabetic retinopathy, as well as in patients with type 1 or type 2 diabetes with macroalbuminuria in whom other causes for proteinuria are absent. DN may also present as a falling estimated glomerular filtration rate with albuminuria as a minor presenting feature, especially in patients taking renin-angiotensin-aldosterone system inhibitors (RAASi). The pathological characteristic features of disease are three major lesions: diffuse mesangial expansion, diffuse thickened glomerular basement membrane, and hyalinosis of arterioles. Functionally, however, the pathophysiology is reflected in dysfunction of the mesangium, the glomerular capillary wall, the tubulointerstitium, and the vasculature. For all diabetic patients, a comprehensive approach to management including glycemic and hypertensive control with RAASi combined with lipid control, dietary salt restriction, lowering of protein intake, increased physical activity, weight reduction, and smoking cessation can reduce the rate of progression of nephropathy and minimize the risk for cardiovascular events. This review focuses on the latest published data dealing with the mechanisms, diagnosis, and current treatment of DN.
Language	English
Publishing date	2014-09-10
Publishing country	Korea (South)
Document type	Journal Article ; Review
ZDB-ID	2656420-8
ISSN	2211-9132
ISSN	2211-9132
DOI	10.1016/j.krcp.2014.08.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials.

Flack, John M / Agarwal, Rajiv / Anker, Stefan D / Pitt, Bertram / Ruilope, Luis M / Rossing, Peter / Adler, Sharon G / Fried, Linda / Jamerson, Kenneth / Toto, Robert / Brinker, Meike / Farjat, Alfredo E / Kolkhof, Peter / Lawatscheck, Robert / Joseph, Amer / Bakris, George L

Kidney medicine

2023 Volume 5, Issue 12, Page(s) 100730

Abstract: Rationale & objective: In FIDELITY, finerenone improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). This analysis explored the efficacy and safety of finerenone in Black patients.: Study design: ... ...

Abstract	Rationale & objective: In FIDELITY, finerenone improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). This analysis explored the efficacy and safety of finerenone in Black patients. Study design: Subanalysis of randomized controlled trials. Setting & participants: Patients with T2D and CKD. Intervention: Finerenone or placebo. Outcomes: Composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure; composite of kidney failure, sustained ≥57% estimated glomerular filtration rate (eGFR) decline from baseline maintained for ≥4 weeks, or renal death. Results: Of the 13,026 patients, 522 (4.0%) self-identified as Black. Finerenone demonstrated similar effects on the cardiovascular composite outcome in Black (HR, 0.79 [95% CI, 0.51-1.24]) and non-Black patients (HR, 0.87 [95% CI, 0.79-0.96; Limitations: Small number of Black patients; analysis was not originally powered to determine an interaction effect based on Black race. Conclusions: The efficacy and safety of finerenone appears consistent in Black and non-Black patients with CKD and T2D. Funding: Bayer AG. Trial registration: ClinicalTrials.gov NCT02540993, NCT02545049. Plain-language summary: Diabetes is a major cause of chronic kidney disease (CKD), affecting more Black adults than White adults. Most adults with CKD ultimately die from heart and vascular complications (eg, heart attack and stroke) rather than kidney failure. This analysis of 2 recent trials shows that the drug finerenone was beneficial for patients with diabetes and CKD. Along with reducing kidney function decline and protein in the urine, it also decreased heart and vascular issues and lowered blood pressure in both Black and non-Black adults with diabetes and CKD. These findings have promising implications for slowing the progression of CKD and protecting against cardiovascular problems in diverse populations.
Language	English
Publishing date	2023-09-28
Publishing country	United States
Document type	Journal Article
ISSN	2590-0595
ISSN (online)	2590-0595
DOI	10.1016/j.xkme.2023.100730
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Dual therapy with an angiotensin receptor blocker and a JAK1/2 inhibitor attenuates dialysate-induced angiogenesis and preserves peritoneal membrane structure and function in an experimental CKD rat model.

Zhang, Pei / Miyata, Kana N / Nast, Cynthia C / LaPage, Janine A / Mahoney, Madisyn / Nguyen, Sonny / Khan, Kamran / Wu, Qiaoyuan / Adler, Sharon G / Dai, Tiane

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis

2022 Volume 43, Issue 2, Page(s) 159–167

Abstract: Background: Peritoneal dialysis (PD) is limited by reduced efficacy over time. We previously showed that a Janus kinase 1/2 inhibitor (JAK1/2i) reduced inflammation, hypervascularity and fibrosis induced by 4.25% dextrose dialysate (4.25%D) ... ...

Abstract	Background: Peritoneal dialysis (PD) is limited by reduced efficacy over time. We previously showed that a Janus kinase 1/2 inhibitor (JAK1/2i) reduced inflammation, hypervascularity and fibrosis induced by 4.25% dextrose dialysate (4.25%D) intraperitoneally (IP) infused for 10 days in rats with normal kidney function. JAK/STAT signalling mediates inflammatory pathways, including angiotensin signalling. We now tested the effect of long-term JAK1/2i and/or an angiotensin receptor blocker (ARB) on peritoneal membrane (PM) in polycystic kidneys (PCK) rats infused with 4.25%D. Methods: Except for controls, all PCK rats had a tunnelled PD catheter: (1) no infusions; (2) 4.25%D; (3) 4.25%D + JAK1/2i (5 mg/kg); (4) 4.25%D +losartan (5 mg/kg); and (5) 4.25%D + losartan +JAK1/2i (5 mg/kg each) IP BID × 16 weeks ( Results: 4.25%D caused hypervascularity, SMCZ widening, fibrosis and UF functional decline in PCK rats. Angiogenesis was significantly attenuated by JAK1/2i ± ARB but not by ARB monotherapy. Both treatments reduced SMCZ area. UF was preserved consistently by dual therapy ( Conclusion: Long-term JAK1/2i ± ARB reduced angiogenesis and fibrosis, and the combination consistently maintained UF. In clinical practice, angiotensin inhibition has been advocated to maintain residual kidney function. Our study suggests that adding JAK1/2i to angiotensin inhibition may preserve PM structure and UF.
MeSH term(s)	Rats ; Animals ; Dialysis Solutions/metabolism ; Peritoneal Dialysis/adverse effects ; Losartan/metabolism ; Losartan/pharmacology ; Angiotensin Receptor Antagonists/metabolism ; Angiotensin Receptor Antagonists/pharmacology ; Angiotensin-Converting Enzyme Inhibitors/metabolism ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Peritoneum/metabolism ; Fibrosis ; Glucose/metabolism ; Angiotensins/metabolism ; Angiotensins/pharmacology ; Renal Insufficiency, Chronic/metabolism
Chemical Substances	Dialysis Solutions ; Losartan (JMS50MPO89) ; Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Glucose (IY9XDZ35W2) ; Angiotensins
Language	English
Publishing date	2022-08-09
Publishing country	United States
Document type	Journal Article
ZDB-ID	645010-6
ISSN	1718-4304 ; 0896-8608
ISSN (online)	1718-4304
ISSN	0896-8608
DOI	10.1177/08968608221116956
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1936: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Prevalence and Management of Diabetic Nephropathy in Western Countries

Satirapoj, Bancha / Adler, Sharon G.

Kidney Diseases

2015 Volume 1, Issue 1, Page(s) 61–70

Institution	Division of Nephrology, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, Calif., USA
Abstract	Background: Diabetic nephropathy (DN) often results in end-stage renal disease, and this is the most common reason for initiation of dialysis in the United States. Complications of diabetes, particularly renal disease, substantially increase the risk of subsequent severe illness and death. The prevalence of DN is still rising dramatically, with concomitant increases in associated mortality and cardiovascular complications. Summary: Renal involvement in type 1 and type 2 diabetes reflects a complex pathogenesis. Various genetic and environmental factors determine the susceptibility and progression to advanced stages of the disease. DN should be considered in patients who have had type 1 diabetes for at least 10 years with microalbuminuria and diabetic retinopathy, as well as in patients with type 1 or type 2 diabetes with macroalbuminuria in whom other causes for proteinuria are absent. The glomerular characteristic features include mesangial expansion, thickened glomerular basement membrane, and hyalinosis of arterioles. The optimal therapy of DN continues to evolve. For all diabetic patients, practical management including blood glucose and blood pressure control with renin-angiotensin-aldosterone blockade combined with lipid control, dietary salt restriction, lowering the dietary protein intake, increased physical activity, weight reduction, and smoking cessation can reduce the rate of progression of nephropathy and cardiovascular disease. Key Messages: DN is a complex disease linking hemodynamic and metabolic pathways with oxidative stress, and systemic inflammation. We summarize the current evidence of epidemiology, clinical diagnosis, and the current management of DN in Western countries. Facts from East and West: The prevalence of DN is increasing in Asia and Western countries alike. The deletion (D) allele of the angiotensin-converting enzyme gene is associated with progression to end-stage renal disease in Asian patients with DN, but this association is uncertain in Europeans. An association between DN and polymorphism of the gene coding for acetyl coenzyme A carboxylase β has been reported in Asian and Western populations. Both in Japan and the US, criteria for diagnosis are a 5-year history of diabetes and persistent albuminuria. Renal biopsy should be done in patients with severe hematuria, cellular casts and - in the US - hepatitis and HIV to rule out other pathologies. Diabetic retinopathy is considered a key criterion in Japan, but the absence of it does not rule out DN in the US. Enlargement of the kidney is observed as a diagnostic criterion in Japan. The differential use of renal biopsy as diagnostic tool might account for a different prevalence between Asian countries. Some Japanese diabetic patients show typical histological alterations for DN with a normal ACR and GFR. The clinical classification is similar between Japan and the US including five stages based on ACR and GFR. The Japanese guidelines do not include blood pressure values for the classification of DN. Guidelines for DN treatment are evolving quickly both in Asia and Western countries based on the numerous clinical trials performed worldwide. Targeting the angiotensin system for its hemodynamic and nonhemodynamic effects is a common approach. DPP-4 inhibitors are widely used in Japan and might have a higher glucose-lowering effect in Asian patients due to their specific diet. A randomized, double-blind placebo-controlled study has been launched to assess the efficacy of the Chinese herbal tea extract Shenyan Kangfu in DN.
Keywords	Diabetic nephropathy ; Chronic kidney disease ; Glomerular hyperfiltration ; Microalbuminuria ; Macroalbuminuria
Language	English
Publishing date	2015-05-01
Publisher	S. Karger AG
Publishing place	Basel, Switzerland
Document type	Article
Note	Diabetic Nephropathy: Review
ZDB-ID	2817963-8
ISSN	2296-9357 ; 2296-9381
ISSN (online)	2296-9357
ISSN	2296-9381
DOI	10.1159/000382028
Database	Karger publisher's database

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito